NRX Pharmaceuticals, Inc. short interest in 2022
In 2022, NRX Pharmaceuticals, Inc.'s disclosed short interest ran from 2.61% of shares outstanding on 14 Jan 2022 to 2.09% on 30 Dec 2022, a change of -0.52 percentage points. The year's high was 5.49% on 14 Apr 2022 and its low 1.87% on 31 Oct 2022, averaging 2.99% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.85 days on 14 Oct 2022. Full history: NRX Pharmaceuticals, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 2.61% (14 Jan 2022)
- End of year
- 2.09% (30 Dec 2022)
- Change
- -0.52 pp
- High
- 5.49% (14 Apr 2022)
- Low
- 1.87% (31 Oct 2022)
- Average
- 2.99%
- Highest days to cover
- 10.85 (14 Oct 2022)
- SEC filings marked
- 5
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 2.61% | 1.36 | |
| 31 Jan 2022 | 3.60% | 2.42 | |
| 15 Feb 2022 | 4.16% | 2.26 | |
| 28 Feb 2022 | 4.81% | 4.85 | |
| 15 Mar 2022 | 4.97% | 3.59 | |
| 31 Mar 2022 | 5.31% | 4.59 | 10-K filed |
| 14 Apr 2022 | 5.49% | 8.15 | |
| 29 Apr 2022 | 3.87% | 5.47 | |
| 13 May 2022 | 2.89% | 3.82 | |
| 31 May 2022 | 2.98% | 1.00 | 10-Q filed |
| 15 Jun 2022 | 2.33% | 1.00 | |
| 30 Jun 2022 | 2.51% | 3.76 | |
| 15 Jul 2022 | 2.29% | 3.60 | |
| 29 Jul 2022 | 2.37% | 1.00 | |
| 15 Aug 2022 | 2.36% | 1.00 | 10-Q filed |
| 31 Aug 2022 | 2.38% | 2.55 | |
| 15 Sep 2022 | 1.92% | 4.46 | |
| 30 Sep 2022 | 2.41% | 6.04 | |
| 14 Oct 2022 | 2.17% | 10.85 | |
| 31 Oct 2022 | 1.87% | 7.59 | |
| 15 Nov 2022 | 1.94% | 4.52 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 2.18% | 1.93 | |
| 15 Dec 2022 | 2.24% | 4.43 | |
| 30 Dec 2022 | 2.09% | 4.88 |
See also: NRX Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.